

Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts)

	Three Months Ended June 30,					Six Months Ended June 30,			
		2019		2018		2019		2018	
Reconciliation of GAAP to Non-GAAP Research and development:									
GAAP Research and development	\$	163,890	\$	137,582	\$	293,017	\$	234,439	
Less: Stock-based compensation expenses		(15,282)		(11,616)		(31,407)		(21,753)	
Non-GAAP Research and development	\$	148,608	\$_	125,966	\$	261,610	\$	212,686	
Reconciliation of GAAP to Non-GAAP Selling, general and administrative:									
GAAP Selling, general and administrative	\$	112,769	\$	84,679	\$	202,377	\$	157,126	
Less: Stock-based compensation expenses		(15,321)		(10,625)		(31,228)		(20,072)	
Non-GAAP Selling, general and administrative	\$_	97,448	\$_	74,054	\$_	171,149	\$	137,054	
Reconciliation of GAAP to Non-GAAP Operating expenses:									
GAAP Operating expenses	\$	280,985	\$	222,261	\$	503,067	\$	391,565	
Less: Stock-based compensation expenses		(30,603)		(22,241)		(62,635)		(41,825)	
Non-GAAP Operating expenses	\$_	250,382	\$_	200,020	\$_	440,432	\$	349,740	
Reconciliation of GAAP to Non-GAAP Net loss:									
GAAP Net loss	\$	(219,481)	\$	(163,560)	\$	(401,396)	\$	(304,774)	
Add: Stock-based compensation expenses		30,603		22,241		62,635		41,825	
Less: Change in fair value of liability obligation		(9,422)		_		(9,422)		_	
Less: Gain on litigation settlement				(20,564)				(20,564)	
Non-GAAP Net loss	\$_	(198,300)	\$_	(161,883)	\$_	(348,183)	\$	(283,513)	
Reconciliation of GAAP to Non-GAAP Net loss per common share-basic and diluted:									
GAAP Net loss per common share - basic and diluted	\$	(2.02)	\$	(1.63)	\$	(3.75)	\$	(3.04)	
Add: Stock-based compensation expenses		0.28		0.22		0.59		0.42	
Less: Change in fair value of liability obligation		(0.09)		_		(0.09)		_	
Less: Gain on litigation settlement				(0.20)				(0.21)	
Non-GAAP Net loss per common share - basic and diluted	\$	(1.83)	\$	(1.61)	\$	(3.25)	\$	(2.83)	